CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 3, 2026
52 Haftlık Aralık
$29–$85
100% of range
Analist Derecelendirmesi
HOLD
21 analysts
Fiyat Hedefi
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Net Kâr Marjı
-6046.2%
Crinetics Pharmaceuticals, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Devamını oku
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
CRNX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$84.77
Piyasa Değeri
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Gelir (TTM)
$8M
Temettü Verimi
—
ROE
-43.0%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$29 – $85
CRNX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$8M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-4.95
2020-12-31
→
2025-12-31
Serbest Nakit Akışı
$-384M
2018-12-31
→
2025-12-31
Marjlar
-6046.2%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
CRNX
Akran Ortalaması
P/E (TTM)
-17.1
47.9
P/S (TTM) (F/S (TTM))
1052.7
16.2
P/B (F/D)
8.2
9.3
Price / FCF (Fiyat / Serbest Nakit Akışı)
-21.1
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
CRNX
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
-6714.8%
—
Net Profit Margin (Net Kâr Marjı)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
CRNX
Akran Ortalaması
Current Ratio (Cari Oran)
12.3
2.7
Quick Ratio (Cari Oran)
12.1
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
CRNX
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
640.7%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
17.6%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
155.3%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
CRNX
Akran Ortalaması
CRNX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
TUT
21 analist
- Güçlü Al 3 14,3%
- Al 4 19,0%
- Tut 14 66,7%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
10 analist · 2026-08-20
Medyan
$85.00
Ortalama
$85.50
← Tüm hedeflerin altında
$84.77
Düşük
$85.00
Yüksek
$90.00
Medyan hedef
$85.00
+0,3%
Ortalama hedef
$85.50
+0,9%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-0.01%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 Mart 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 Aralık 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 Eylül 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 Haziran 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 Mart 2025 | $-1.04 | $-0.96 | -0.08% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Bilanço 24
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Nakit Akışı 13
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Likidite ve Solventlik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Değerleme (TTM) 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Gelir Tablosu 15
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Bilanço 23
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Nakit Akışı 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Kârlılık 6
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Verimlilik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $8M | $1M | $4M | $5M | $1M |
| Faaliyet Kâr Marjı % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Net Gelir | $-465M | $-298M | $-215M | $-164M | $-108M |
| Seyreltilmiş Hisse Başı Kâr | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Cari Oran | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-384M | $-230M | $-171M | $-117M | $-89M |
Son Haberler Bu şirketten bahseden son manşetler
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 287 dosya · $3.2B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 63 (+11 önceki Ç'ye göre) | 30 (-13 önceki Ç'ye göre) | 95 (-17 önceki Ç'ye göre) | 63 (+3 önceki Ç'ye göre) | +11.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| FMR LLC | $486.250.673 | 12.994.406 | 15,13% | Hisse senetleri |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336.372.047 | 8.989.098 | 10,46% | Hisse senetleri |
| Driehaus Capital Management LLC | $241.866.078 | 6.463.551 | 7,52% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $237.002.526 | 6.333.579 | 7,37% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180.836.416 | 4.832.614 | 5,63% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $177.567.704 | 4.745.262 | 5,52% | Hisse senetleri |
| STATE STREET CORP | $100.635.477 | 2.689.350 | 3,13% | Hisse senetleri |
| Bellevue Group AG | $98.040.400 | 2.620.000 | 3,05% | Hisse senetleri |
| BAKER BROS. ADVISORS LP | $87.991.820 | 2.351.465 | 2,74% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $87.542.675 | 2.338.905 | 2,72% | Hisse senetleri |
| Polar Capital Holdings Plc | $85.108.460 | 2.274.411 | 2,65% | Hisse senetleri |
| Pictet Asset Management Holding SA | $77.572.984 | 2.075.375 | 2,41% | Hisse senetleri |
| Siren, L.L.C. | $53.165.887 | 1.420.788 | 1,65% | Hisse senetleri |
| First Light Asset Management, LLC | $50.923.606 | 1.360.866 | 1,58% | Hisse senetleri |
| NOVO HOLDINGS A/S | $49.394.400 | 1.320.000 | 1,54% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $47.245.129 | 1.262.562 | 1,47% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $45.730.234 | 1.222.080 | 1,42% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $44.555.208 | 1.190.679 | 1,39% | Hisse senetleri |
| MONTANOVA CAPITAL, LLC | $44.390.560 | 1.186.279 | 1,38% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $37.382.580 | 999.000 | 1,16% | Hisse senetleri |
| Hood River Capital Management LLC | $36.259.830 | 968.996 | 1,13% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $34.657.132 | 926.166 | 1,08% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32.841.401 | 877.643 | 1,02% | Hisse senetleri |
| Aberdeen Group plc | $30.699.181 | 820.395 | 0,95% | Hisse senetleri |
| Candriam S.C.A. | $30.618.690 | 819.032 | 0,95% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $28.230.995 | 754.436 | 0,88% | Hisse senetleri |
| Fisher Asset Management, LLC | $27.748.912 | 741.553 | 0,86% | Hisse senetleri |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17.709.036 | 479.400 | 0,55% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $17.451.149 | 466.356 | 0,54% | Hisse senetleri |
| Impax Asset Management Group plc | $16.277.700 | 435.000 | 0,51% | Hisse senetleri |
| Prosight Management, LP | $14.020.002 | 374.666 | 0,44% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13.991.714 | 373.910 | 0,44% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.685.018 | 365.714 | 0,43% | Hisse senetleri |
| BRAUN STACEY ASSOCIATES INC | $13.027.511 | 348.143 | 0,41% | Hisse senetleri |
| Fiera Capital Corp | $12.395.263 | 331.247 | 0,39% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $11.271.877 | 301.226 | 0,35% | Hisse senetleri |
| Defilade Capital Management, L.P. | $8.959.845 | 239.440 | 0,28% | Hisse senetleri |
| SEB Asset Management AB | $8.003.786 | 213.891 | 0,25% | Hisse senetleri |
| Foresite Capital Management VI LLC | $7.933.414 | 212.010 | 0,25% | Hisse senetleri |
| RICE HALL JAMES & ASSOCIATES, LLC | $7.346.220 | 196.318 | 0,23% | Hisse senetleri |
| TD Asset Management Inc | $7.152.534 | 191.142 | 0,22% | Hisse senetleri |
| Swiss National Bank | $6.877.796 | 183.800 | 0,21% | Hisse senetleri |
| SEGALL BRYANT & HAMILL, LLC | $6.855.307 | 183.199 | 0,21% | Hisse senetleri |
| BlackRock, Inc. | $6.781.290 | 181.221 | 0,21% | Hisse senetleri |
| JENNISON ASSOCIATES LLC | $6.056.839 | 161.861 | 0,19% | Hisse senetleri |
| New Leaf Venture Partners, L.L.C. | $5.872.650 | 141.000 | 0,18% | Hisse senetleri |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5.865.136 | 156.738 | 0,18% | Hisse senetleri |
| Foresite Capital Management IV, LLC | $5.613.000 | 150.000 | 0,17% | Hisse senetleri |
| Bank of New York Mellon Corp | $5.581.754 | 149.165 | 0,17% | Hisse senetleri |
| NEW YORK STATE COMMON RETIREMENT FUND | $5.508.898 | 147.218 | 0,17% | Hisse senetleri |
| ENVESTNET ASSET MANAGEMENT INC | $5.471.384 | 146.216 | 0,17% | Hisse senetleri |
| Moody Aldrich Partners LLC | $5.466.201 | 146.077 | 0,17% | Hisse senetleri |
| Ishara Investments LP | $5.369.770 | 143.500 | 0,17% | Hisse senetleri |
| CITADEL ADVISORS LLC | $5.176.271 | 138.329 | 0,16% | Hisse senetleri |
| RHUMBLINE ADVISERS | $4.861.141 | 129.908 | 0,15% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $4.782.618 | 131.680 | 0,15% | Hisse senetleri |
| GordonMD Global Investments LP | $4.751.779 | 126.985 | 0,15% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4.712.974 | 125.948 | 0,15% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $4.700.428 | 129.392 | 0,15% | Hisse senetleri |
| Cormorant Asset Management, LP | $4.677.500 | 125.000 | 0,15% | Hisse senetleri |
| SECTOR GAMMA AS | $4.289.380 | 114.628 | 0,13% | Hisse senetleri |
| XTX Topco Ltd | $4.164.547 | 111.292 | 0,13% | Hisse senetleri |
| ALPS ADVISORS INC | $3.981.825 | 106.409 | 0,12% | Hisse senetleri |
| FEDERATED HERMES, INC. | $3.957.390 | 105.756 | 0,12% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3.834.048 | 105.563 | 0,12% | Hisse senetleri |
| Nuveen Asset Management, LLC | $3.760.151 | 73.541 | 0,12% | Hisse senetleri |
| Burkehill Global Management, LP | $3.742.000 | 100.000 | 0,12% | Hisse senetleri |
| Nuveen, LLC | $3.619.262 | 96.720 | 0,11% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $3.484.251 | 93.112 | 0,11% | Hisse senetleri |
| MORGAN STANLEY | $3.320.829 | 88.744 | 0,10% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $3.266.729 | 87.299 | 0,10% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $3.254.754 | 86.979 | 0,10% | Hisse senetleri |
| AWM Investment Company, Inc. | $3.180.700 | 85.000 | 0,10% | Hisse senetleri |
| Odyssean, LLC | $3.160.344 | 84.456 | 0,10% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $2.806.500 | 75.000 | 0,09% | Hisse senetleri |
| ALGERT GLOBAL LLC | $2.714.147 | 72.532 | 0,08% | Hisse senetleri |
| ExodusPoint Capital Management, LP | $2.652.404 | 70.882 | 0,08% | Hisse senetleri |
| Ensign Peak Advisors, Inc | $2.507.290 | 67.004 | 0,08% | Hisse senetleri |
| BARCLAYS PLC | $2.466.127 | 65.904 | 0,08% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $2.370.631 | 63.352 | 0,07% | Hisse senetleri |
| Man Group plc | $2.284.229 | 61.043 | 0,07% | Hisse senetleri |
| MetLife Investment Management, LLC | $2.258.709 | 60.361 | 0,07% | Hisse senetleri |
| CITIGROUP INC | $2.255.229 | 60.268 | 0,07% | Hisse senetleri |
| Longaeva Partners L.P. | $2.184.879 | 58.388 | 0,07% | Hisse senetleri |
| Swedbank AB | $2.155.392 | 57.600 | 0,07% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.068.016 | 55.265 | 0,06% | Hisse senetleri |
| Jump Financial, LLC | $1.923.388 | 51.400 | 0,06% | Hisse senetleri |
| Lighthouse Investment Partners, LLC | $1.871.000 | 50.000 | 0,06% | Hisse senetleri |
| Vestmark Advisory Solutions, Inc. | $1.823.252 | 48.724 | 0,06% | Hisse senetleri |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.787.254 | 47.762 | 0,06% | Hisse senetleri |
| VANGUARD GROUP INC | $1.774.626 | 38.123 | 0,06% | Hisse senetleri |
| Point72 Asset Management, L.P. | $1.735.577 | 46.381 | 0,05% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $1.696.398 | 45.334 | 0,05% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $1.606.254 | 42.925 | 0,05% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.549.188 | 41.400 | 0,05% | Alım opsiyonu |
| Invesco Ltd. | $1.545.446 | 41.300 | 0,05% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $1.485.986 | 39.711 | 0,05% | Hisse senetleri |
| HighMark Wealth Management LLC | $1.444.224 | 38.595 | 0,04% | Hisse senetleri |
| OAK RIDGE INVESTMENTS LLC | $1.405.046 | 37.548 | 0,04% | Hisse senetleri |
| Orion Porfolio Solutions, LLC | $1.404.234 | 37.526 | 0,04% | Hisse senetleri |
Şirket yöneticileri 20 içeriden öğrenenler · 9 yöneticiler · 10 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 Mart 2025 A | 52.000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 Eylül 2024 M | 111.092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 Mart 2025 S | 87.491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 Haziran 2025 M | 99.713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 Mart 2025 S | 72.233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 Ocak 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 05 Temmuz 2024 M | 29.259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 Ekim 2023 M | 43.210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 Şubat 2022 A | 176.995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Yönetim kurulu üyesi | 02 Temmuz 2026 S | 19.225 | 0 | 1 | $-120.000 |
| Caren Deardorf | Yönetim kurulu üyesi | 18 Haziran 2026 A | 22.225 | 0 | 0 | $0 |
| Weston Nichols | Yönetim kurulu üyesi | 18 Haziran 2026 A | 22.225 | 0 | 0 | $0 |
| Stephanie Okey | Yönetim kurulu üyesi | 18 Haziran 2026 A | 12.325 | 0 | 2 | $-246.143 |
| Matthew K Fust | Yönetim kurulu üyesi | 18 Haziran 2026 A | 28.761 | 0 | 0 | $0 |
| Camille L Bedrosian | Yönetim kurulu üyesi | 18 Haziran 2026 A | 22.225 | 0 | 0 | $0 |
| Wendell Wierenga | Yönetim kurulu üyesi | 18 Haziran 2026 A | 122.071 | 0 | 0 | $0 |
| Wendall Wierenga | Yönetim kurulu üyesi | 11 Haziran 2025 A | 116.146 | 0 | 0 | $0 |
| Stephen W Kaldor | Yönetim kurulu üyesi | 19 Haziran 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Yönetim kurulu üyesi | 21 Haziran 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 07 Ağustos 2026 M | 424.706 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 başvurular | 01 Mart 2024 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 55 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107.892 NS | 31 Mayıs 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 1,65% | 19.000 NS | 31 Mayıs 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4.666 NS | 30 Nisan 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18.743 NS | 30 Nisan 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11.043 NS | 31 Mayıs 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,28% | 93.045 NS | 30 Nisan 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38.553 NS | 30 Nisan 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3.872 NS | 31 Mayıs 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3.142 NS | 30 Nisan 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18.879 NS | 30 Nisan 2026 | N-PORT |
| RSSL · Global X Funds | 0,12% | 42.391 NS | 30 Nisan 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31.759 NS | 30 Nisan 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4.601 NS | 31 Mayıs 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492.431 NS | 31 Mayıs 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24.991 NS | 30 Nisan 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41.183 NS | 30 Nisan 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196.549 NS | 30 Nisan 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3.599 NS | 31 Mayıs 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5.196 NS | 30 Nisan 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 Mayıs 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3.643 NS | 31 Mayıs 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5.689 NS | 31 Mayıs 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3.773 NS | 31 Mayıs 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 Mayıs 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 125.853 NS | 30 Nisan 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28.694 NS | 31 Mayıs 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5.863 NS | 30 Nisan 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3.388 NS | 30 Nisan 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,01% | 31.413 NS | 30 Nisan 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,01% | 15.024 NS | 30 Nisan 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,01% | 60.503 NS | 31 Mayıs 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 468 NS | 30 Nisan 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VBK · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 Temmuz 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| ITOT · iShares Trust | — | — | 05 Ağustos 2026 | Günlük |
| IWV · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IWO · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IWM · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IBB · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IHE · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 04 Ağustos 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | — | — | 13 Temmuz 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | — | — | 20 Temmuz 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | — | — | 30 Temmuz 2026 | Günlük |